



DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: <http://grants.nih.gov/grants/olaw/olaw.htm>

FOR EXPRESS MAIL:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 480-3387

June 4, 2020

Re: Animal Welfare Assurance
A3464-01 [OLAW Case 10N]

Dr. David M. Anderson
Executive Director
Health Sciences Administration
University of Washington
(b) (4) Health Sciences Center, Box 356355
Seattle, WA 98195-6355

Dear Dr. Anderson,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your 26 May 2020 letter reporting a noncompliance with the PHS Policy on the Humane Care and Use of Laboratory Animals at the University of Washington. Your letter supplements the prompt telephone report received in this office on May 6, 2020. According to the information provided it is understood that subsequent to surgery, three rats died due to an overdose of xylazine. Two rats died during the surgery and one rat was found dead the day after surgery. A recently acquired bottle of xylazine was a higher concentration than normally used (100 mg/mL versus 20 mg/mL).

Corrective and preventive action: The lab has implemented a policy of triple checking the concentration of stock drug bottles - once when received, once when the bottle is brought from "in reserve" to "active" status and again every time drug is drawn from the bottle. No unallowable PHS funds were associated with this event.

OLAW believes that the corrective and preventive measures put in place by the University of Washington are consistent with the provisions of the PHS Policy on Humane Care and Use of Laboratory Animals for institutional self-monitoring and self-reporting. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse -S

Digitally signed by Brent C. Morse

-S
Date: 2020.06.04 13:48:44 -04'00'

Brent C. Morse, DVM
Director
Division of Compliance Oversight
Office of Laboratory Animal Welfare

cc: IACUC contact

HEALTH SCIENCES ADMINISTRATION
Office of the Executive Director

26 May 2020

Dr. Brent Morse olawdco@od.nih.gov
Office of Animal Welfare, NIH
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, MD 20892

Re: D16-00292 (A3464-01), Rat mortality related to anesthesia

Dear Dr. Morse:

This is a final report on a situation reported to OLAW by Dr. Stocking in a telephone call on 5/6/2020.

3 rats had spinal injury surgery on the same day. Two rats died during the surgery and one rat was found dead the day after surgery. After surgery the group realized the rats had received an overdose of xylazine. These animals were anesthetized with a recently acquired bottle of xylazine which was at a higher concentration than normally used (100 mg/mL versus 20 mg/mL).

Corrective Action: The lab has implemented a policy of triple checking the concentration of stock drug bottles - once when received, once when the bottle is brought from "in reserve" to "active" status and again every time drug is drawn from the bottle to make a dilution for ketamine/xylazine anesthesia..

The IACUC reviewed the incident at its May meeting and vote to send the PI a letter acknowledging their prompt self-reporting of this incident. The IACUC considers the case closed. No unallowable PHS funds were associated with this event.

If you have questions regarding this situation or require additional information, please don't hesitate to contact me.

Sincerely,

(b) (6)

David M. Anderson, D.V.M.
Executive Director, Health Sciences Administration
Institutional Official

cc: Dr. Jane Sullivan
 Dr. Kim Stocking

Wolff, Axel (NIH/OD) [E]

From: OLAW Division of Compliance Oversight (NIH/OD)
Sent: Wednesday, May 27, 2020 7:16 AM
To: (b) (6)
Cc: OLAW Division of Compliance Oversight (NIH/OD)
Subject: RE: Final reports of non-compliances

Thank you for these reports, (b) (6) We will send replies soon.

Axel Wolff, M.S., D.V.M.
Deputy Director, OLAW

From: (b) (6)
Sent: Tuesday, May 26, 2020 1:11 PM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Cc: David M. Anderson <danderso@uw.edu>; Jane Sullivan <jmsull@uw.edu>; Kim Stocking <kstock@uw.edu>
Subject: Final reports of non-compliances

Please see the attached 3 final reports of noncompliance at the University of Washington. Let me know if you have any questions.

(b) (6)

(b) (6)

W UNIVERSITY of WASHINGTON



Initial Report of Noncompliance

By: Brent

Date: 5/7/2020

Time: Voicemail

Name of Person reporting: Kim Stocking, AV

Telephone #: (b) (6)

Fax #:

Email:

Name of Institution: U. of Washington

Assurance number: A3464

Did incident involve PHS funded activity? ?

Funding component:

Was funding component contacted (if necessary):

What happened? Three rats died during spinal injury surgery after receiving an overdose of Xylazine (new bottle with higher concentration than previously used).

Species involved: Rat

Personnel involved: Researchers

Dates and times: 3/13/2020

Animal deaths:

Projected plan and schedule for correction/prevention (if known):

Lab will double check drugs upon receipt and when used.

Projected submission to OLAW of final report from Institutional Official:

OFFICE USE ONLY

Case #